(Alliance News) - nanosynth group PLC on Wednesday said it recently completed successful trials that have enabled it to incorporate its antiviral technology into heating, ventilation, and air conditioning units for filtration maker Volz Holdings VOS.
Shares in nanosynth were up 17% at 0.60 pence on Wednesday in London.
nanosynth is a Nottingham-based firm that specialises in the synthesis and application of nanoparticles to create new products and improve on existing ones.
Nanosynth explained that the UK Health & Safety Executive approved Pharm 2 Farm Ltd, one of its subsidiaries, for REACH UK registration following the completion of successful trials.
REACH registration relates to the authorisation and restriction of chemicals, and the approval has allowed Volz to use the firm's antiviral technology.
"We are delighted by these extremely positive trial results and the important REACH UK registration which will allow our partner, Volz, to apply our antiviral technology to all of their products. This has the potential to lead to wider adoption by the global filtration industry. A pipeline of interest is already at an advanced stage, and we are hopeful that this will lead to considerable sales for our first to market antiviral product," said Chief Executive Mark Duffin.
The UK Health & Safety Executive has now also allocated Pharm 2 Farm to the appropriate substance tonnage band.
This will allow the production and distribution of up to 100 tonnes of copper oxide nano-material per year, nanosynth explained.
This exceeds the company's preliminary year one forecast copper oxide nano-material sales requirements for the antiviral heating, ventilation, and air conditioning market.
As a result, nanosynth expects it will be able to quickly expand into other antipathogenic projects moving forward.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
